Mind Medicine (MindMed) Inc. (DFTX)
| Market Cap | 1.48B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -168.10M |
| Shares Out | 98.51M |
| EPS (ttm) | -1.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,061,920 |
| Open | 14.86 |
| Previous Close | 14.87 |
| Day's Range | 14.31 - 15.16 |
| 52-Week Range | 4.70 - 15.29 |
| Beta | 2.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 5, 2026 |
About DFTX
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or “Definium") is updating its previous announcement that the Company's Common Shares woul...
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026
NEW YORK--(BUSINESS WIRE)--MindMed Announces Rebrand to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026.
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Announces New Employee Inducement Grant
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Announces New Employee Inducement Grants
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. ( MNMD) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Robert Barrow - CEO & Director Daniel Karlin - Chief Medical Officer Brandi Roberts - Chie...
MindMed Reports Q3 2025 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
MindMed to Participate in Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed to Report Q3 2025 Financial Results on November 6, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy
Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and extend...
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health di...
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidat...
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
MindMed to Participate in September Investor Conferences
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Me...
MindMed Reports Q2 2025 Financial Results and Business Updates
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
MindMed to Participate in June Investor Conferences
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to tr...
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to t...
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive ...